mgta-145
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 22, 2019 (NCT03932864)
Timeline
Indications
Mechanism of action
- Interleukin-8 receptor BAGONIST
CXCR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445128 | Phase 2 | Jun 24, 2022 | bluebird bio, Magenta Therapeutics |
| NCT04762875 | Phase 2 | Jun 16, 2021 | Magenta Therapeutics, National Marrow Donor Program |
| NCT04552743 | Phase 2 | Oct 5, 2020 | Stanford University |
| NCT04154670 | Phase 1 | Nov 7, 2019 | Magenta Therapeutics |
| NCT03932864 | Phase 1 | Apr 22, 2019 | Magenta Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Magenta Therapeutics | For profit | 4 | 4 | 2 | 2019 |
| bluebird bio | For profit | 1 | 0 | 1 | 2022 |
| National Marrow Donor Program | Government | 1 | 0 | 1 | 2021 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1